体素内不相干运动联合生物标志物在非小细胞肺癌疗效评价中的应用

doi:10.19739/j.cnki.issn1001-9510.2020.03.004

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1317 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the role of IVIM parameters and serum VEGF and HIF-1α in evaluating the efficacy of chemoradiotherapy for advanced non-small cell lung cancer (NSCLC).Methods Fifty-nine cases of advanced NSCLC were treated with chemoradiotherapy. IVIM was performed before and after treatment, and the parameters before and after treatment were obtained by post-treatment software,serum VEGF and HIF-1α levels were obtained before and after treatment.Response to chemoradiotherapy was assessed as complete response (CR), partial response (PR), disease stability (SD) and disease progression (PD) according to RECIST 1.1. CR and PR were classified as curative effect sensitive group.SD and PD were classified as efficacy insensitivity group.The independent sample T test was used to compare the changes of each parameter value before and after treatment between the two groups, and the ROC curve was used to analyze each parameter to judge the evaluation efficacy of concurrent chemoradiotherapy for advanced NSCLC, and the optimal threshold was determined.Results Serum VEGF and HIF-1α in NSCLC patients were significantly higher than those in healthy volunteers (P<0.01).IVIM parameters and serum VEGF and HIF-1α levels were correlated with age, stage and pathological type (P<0.05).D value, f value, D change value, VEGF, VEGF change value, HIF-1α value, HIF-1α change value after treatment have certain value in predicting short-term efficacy (P<0.05).When the change value of D and the change value of HIF-1α were 0.29×10^-3mm²/s and 0.29ng/mL, respectively, the predictive efficacy of chemoradiotherapy was the best.VEGF and HIF-1α combined with IVIM parameters can improve the prediction of chemoradiotherapy efficacy.Conclusion VEGF and HIF-1α alone or in combination with IVIM parameters can be used as effective indicators for early prediction of NSCLC chemoradiotherapy efficacy.

Key words： lung cancer magnetic resonance imaging incoherent motion in voxel VEGF HIF-1α

Received: 16 December 2019

PACS:

R734

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Xia
	CHEN Yinghai
	DU Chunjuan
	LIU Zhibing
	LI Mianli
	LIU Changmin

Cite this article:

HAN Xia,CHEN Yinghai,DU Chunjuan, et al. Application of intra-voxel incoherent motion combined with biomarker in the evaluation of efficacy of non-small cell lung cancer[J]. 滨州医学院学报, 2020, 43(3): 172-177.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2020.03.004 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2020/V43/I3/172

[1] ALHAJJ N, CHEE C F, WONG T W, et al. Lung cancer: active therapeutic targeting and inhalational nanoproduct design[J]. Expert Opin Drug Deliv, 2018, 15(12): 1223-1247.
[2] WATNABE H, OKADA M, KAJI Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1) [J]. Gan to Kagaku Ryoho Cancer & Chemotherapy, 2009, 36(13):2495-501.
[3] MAHAJAN A,VRK R,ANANTARAM G.Clinical-radiological-pathological correlation of cavernoussinushemangioma:incremental value of diffusion weighted imaging [J].World J Radiol,2017,9(8) :330-338.
[4] CHAVHAN G B, ALSABBAN Z, BABYN P S. Diffusion-weighted imaging in pediatric body MR imaging: principles, technique, and emerging applications[J]. Radiographics A Review Publication of the Radiological Society of North America Inc, 2014, 34(3):E73.
[5] LE BIHAN D, BRETON E, LALLEMAND D, et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders[J]. Radiology, 1986,161:401-407.
[6] 陈小莉.应用 IVIM 与 DWI 评价及预测晚期宫颈癌同步放化疗疗效临床价值初探[D].兰州:兰州大学临床医学院,2018.
[7] SHIROTA N, SAITO K, SUGIMOTO K, et al. Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study[J]. Cancer imaging, 2016, 16:1.
[8] CHE S, ZHAO X, OU Y, et al. Role of the intravoxel incoherent motion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer[J]. Medicine, 2016, 95(4):2420.
[9] XU Q, XU Y, SUN H, et al. Quantitative intravoxel incoherent motion parameters derived from whole-tumor volume for assessing pathological complete response to neoadjuvant chemotherapy in locally advanced rectal cancer.[J]. Journal of Magnetic Resonance Imaging Jmri, 2017, 15(5):168-178.
[10] LIU Y, SUN H, BAI R, et al. Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study[J]. Radiation Oncology, 2015, 10(1):185.
[11] 蔡靖.磁共振功能成像及分子标记指导局部晚期非小细胞肺癌同步放化疗的疗效研究[D].南昌:南昌大学,2017.
[12] 李妹.磁共振 IVIM-DWI 在肺癌化疗前后变化特点的研究[D].北京:中国人民解放军军事医学科学院,2017.
[13] NOUGARET S, VARGAS H A, LAKHMAN Y, et al. Intravoxel incoherent motion-derived histogram metrics for assessment of response after combined chemotherapy and radiation therapy in rectal cancer: initial experience and comparison between single-section and volumetric analyses [J]. Radiology, 2016, 280(2):150702.
[14] FURRUKH M,BURNEY I A,KUMAR S,et al.Improving outcomes in advanced lung cancer: Maintenance therapy in non-small-cell lung carcinoma [J]. Sultan Qaboos Univ Med J,2013,13( 1): 3-18.
[15] 韩忠,吴文川,李华,等.非小细胞肺癌组织中VEGF、P-ACC、LKB1表达变化与微血管密度的关系[J].山东医药, 2018,58(34):41-43.
[16] 宋琳婧,张培先,龙轶,等.肺癌患者血清VEGF表达水平与临床病理特征的相关性研究[J].检验医学与临床,2019,16(9):1257-1259.
[17] ROSKOSKI R J. Vascularendothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinoma [J].Pharmacol Res,2017,120(3):116-132.
[18] 杨扬,樊美荣,王鲁, 等.血清VEGF对非小细胞肺癌患者治疗疗效评估的指导意义[J].标记免疫分析与临床,2018,25(9):1257-1259.